Phase-3 Clinical Trials of Adjunctive Therapy with Preladenant, an Adenosine 2a Antagonist, in Patients with Parkinson’s Disease (P7.087)Robert A. Hauser, David Hewitt, Kenneth Wolski et al.|Neurology|2014Cited by 13
Phase-3 Clinical Trial of the Adenosine 2a Antagonist Preladenant, Given as Monotherapy, in Patients with Parkinson’s Disease (S7.004)Fabrizio Stocchi, David Hewitt, Olivier Rascol et al.|Neurology|2014Cited by 6
Post-hoc Analyses of Phase-3 Data with Preladenant, an Adenosine 2a Antagonist, in Patients with Parkinson’s Disease (P7.088)Olivier Rascol, Susan Huyck, David Hewitt et al.|Neurology|2014Cited by 1